Context Therapeutics is trading 6.97% down at $0.48, with no company-specific announcement or confirmed overnight catalyst identified for August 21, 2026.
- The stock gained 6.61% on August 20 after losing 6.37% on August 18.
- Broader U.S. futures are modestly higher, so overall market weakness does not appear to be driving the move.
- Continued volatility in a low-priced biotech stock is the most likely explanation.